However, this approach is limited by moderate responses, due to insufficient expansion of transferred T cells and inefficient trafficking to tumor regions [119], as well as potential severe side effects characterized by “cytokine storm” with TNF, IFN-γ and IL-6 when IL-2 is systemically co-administered with T cells [120]. The gene discussed is IL2; the disease is neoplasm.